Opinion

Video

Dr Parrondo’s Frontline CLL Treatment Approach for Pre-existing HTN and Afib

Author(s):

Catherine C. Coombs, MDMatthew S. Davids, MD, MMSc

The panelists explore strategies for managing front-line chronic lymphocytic leukemia (CLL) treatment in patients with pre-existing hypertension and atrial fibrillation.

  1. The panelists explore strategies for managing front-line chronic lymphocytic leukemia (CLL) treatment in patients with pre-existing hypertension and atrial fibrillation.
Related Videos
2 KOLs are featured in this program.
2 KOLs are featured in this program.
2 KOLs are featured in this series
2 KOLs are featured in this series
A panel of 5 experts on breast cancer
5 KOLs are featured in this peer exchange
A panel of 5 experts on breast cancer
5 KOLs are featured in this peer exchange
Mazyar Shadman, MD, MPH
2 KOLs are featured in this series
Related Content
Yucai Wang, MD, PhD, Mayo Clinic
July 22nd 2024

Pembrolizumab Plus B-Cell Receptor Inhibitors Generates Response in Richter Transformation of CLL/SLL

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Orelabrutinib Plus FCG Generates Rapid Molecule Remissions in CLL
July 3rd 2024

First-Line Orelabrutinib Plus FCG Generates Rapid Molecule Remissions in CLL

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

Arliene Ravelo Mangalindan, MPH, director, Oncology Health Economics & Outcomes Research, Genentech
June 18th 2024

Patients With CLL Place the Most Value on Treatments That Prolong PFS

Stephen Opat, of Monash Health
June 17th 2024

Sonrotoclax Plus Zanubrutinib Is Safe, Efficacious in Relapsed/Refractory CLL/SLL